Gynecologic Cancer News

The ideal strategy to treat cancer with cell therapy can vary greatly depending on tumor type.

Active systemic cancer treatment did not appear associated with increased mortality among patients with cancer and COVID-19, according to study results published in JAMA Network Open.

The FDA granted accelerated approval to dabrafenib plus trametinib for treatment of certain patients with unresectable or metastatic solid tumors that harbor BRAF V600E mutations.

Risks for severe maternal morbidity and mortality appeared higher among pregnancies complicated by cancer, according to study results in a research letter published in JAMA Oncology.

Vaccinated patients with cancer had significantly higher risks for breakthrough COVID-19 infection, especially those undergoing active cancer care, compared with individuals without cancer, according to a study published in JAMA Oncology.

Women with recurrent ovarian cancer experience an average of 14 disease or treatment-related symptoms at any given time over the course of their disease.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2022 ASCO Annual Meeting, as well as Healio’s top headlines from the meeting.

Obesity appeared associated with improved immunotherapy outcomes among patients with certain cancer types, according to a cohort study published in JAMA Network Open.

CHICAGO – Healio gathered the best, brightest and boldest group of oncologists during the ASCO Annual Meeting in Chicago to celebrate our inaugural Healio Disruptive Innovators.

CHICAGO — Intermittent relacorilant plus nab-paclitaxel demonstrated an OS benefit among women with recurrent platinum-resistant/refractory ovarian cancer compared with nab-paclitaxel alone.